CAR T-Cell Isoform Targeting for CD19 Relapse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CD19-related cancers, such as CART19 therapy, face challenges with CD19 negative relapses due to alternative splicing of the CD19 gene, where isoforms like Δex2 and Δex5-6 evade recognition, leading to treatment resistance.
Innovation Solution
Administering Src family kinase inhibitors like dasatinib and using chimeric antigen receptor-modified T cells specific for CD19 isoforms, CD20, and CD22, along with nucleic acids encoding these receptors, to target and treat cancers expressing CD19 isoforms, particularly those that have developed resistance to conventional CART19 therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CART19 therapy is used to treat CD19-related cancers, then initial treatment efficacy is improved, but relapse resistance develops due to alternative splicing of CD19 gene
Solution Approach 1:
The patent changes the targeting parameters by developing CARs that recognize alternative CD19 isoforms (Δex2, Δex5-6) instead of only wild-type CD19. This involves modifying the CAR antigen-binding domains to specifically bind to epitopes present in splice variants while avoiding recognition of the original target, thereby adapting to the compositional changes in CD19 expression during disease progression.
Solution Approach 2:
The therapeutic approach transitions from a static CAR design targeting a fixed CD19 epitope to a dynamic strategy that adapts to changing CD19 isoform expressions. The system evolves by selecting and deploying CARs targeting different CD19 isoforms based on the specific relapse pattern, enabling the therapy to dynamically respond to the tumor's compositional changes.
2Productivity
If conventional CART19 therapy is administered, then initial response is achieved, but CD19 negative relapses occur due to isoform evasion
Solution Approach 1:
The patent segments the CD19 antigen into multiple isoform-specific epitopes (wild-type CD19, Δex2 CD19, Δex5-6 CD19). Instead of targeting a single epitope, the therapy divides the antigen recognition into distinct segments, allowing CARs to be designed against each specific isoform variant. This segmentation enables the immune system to target different portions of the CD19 protein depending on which isoform is expressed in the relapsed disease.
Solution Approach 2:
The patent introduces a new dimension of specificity by targeting the splice-site specific epitopes that differentiate CD19 isoforms. Rather than focusing solely on the presence or absence of CD19, the therapy adds an additional layer of discrimination based on the specific epitopic structure created by alternative splicing, thereby achieving isoform-specific recognition that prevents relapse.
3Reliability
If Src family kinase inhibitors are combined with CAR therapy, then treatment resistance is overcome, but therapeutic complexity increases
Solution Approach 1:
The patent uses Src family kinase inhibitors as intermediary agents that modulate the signaling pathways involved in CD19 isoform expression and CAR T-cell function. These inhibitors act as mediators between the CAR therapy and the tumor cells, enhancing the efficacy of CAR-mediated cytotoxicity by blocking downstream signaling that would otherwise promote resistance mechanisms and isoform stability.
Data Source
AI summary
Compositions and methods for inhibiting, treating, and/or preventing a B-cell neoplasm are provided.